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Hospitals (ATIH). Costs and outcomes were discounted at 4% through 30 years and 
2% thereafter. Robustness of results was assessed using sensitivity analyses. The 
assessed outcomes were the incremental cost per quality-adjusted life-year (QALY) 
gained and total life-years gained (LYG). Results: This study will inform public 
decision making about reimbursement of mild-to-moderate OSAHS treatments. 
CPAP was associated with higher costs and QALYs compared with dental devices, 
lifestyle advice and no treatment. Several sensitivity analyses were undertaken 
and it was found that the most sensitive parameters were related to sleepiness and 
cardiovascular inputs. Further investigation (clinical trial/observational study) of 
treatment effects on these parameters is needed. ConClusions: This analysis is 
the first to assess the cost-effectiveness of treatments in mild-to-moderate OSAHS 
patients in France. The technical report of this research will be available on the 
HAS website at the time of the congress (November 2014).
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objeCtives: Allergic rhinitis – hay fever and mite hypersensitivity - is a prevalent 
and increasingly common condition, causing considerable morbidity and eco-
nomic burden to society. A minority of patients have an indication for subcutane-
ous immunotherapy (SCIT). SCIT using extracts of tree pollen, grass pollen and/or 
house dust mite is common practice in The Netherlands, Europe and beyond. SCIT 
is widely reimbursed, but very few prospective cost-effectiveness studies have been 
done. Methods: An open-label, 2-year, multicenter, randomized controlled trial 
with two parallel treatment arms was performed, comparing SCIT + usual care (UC) 
with UC alone, using online resource use and labor productivity questionnaires, and 
electronic versions of EQ-5D®, SF-36® and a global subjective assessment of symp-
toms (GA). Primary endpoints were the costs per QALY, costs per successfully treated 
patient and the cost per additional symptom-free day. A Generalized Estimation 
Equation (GEE) model was estimated with mean two-week health care/societal costs 
as dependent variable, followed by a 1000-iteration bootstrap procedure. Results: 
A total of 183 adult patients aged 18 to 45 years with persistent moderate to severe 
allergic rhinitis due to one (43%) or more (57%) allergies (93 SCIT+UC, 90 UC) were 
included. There were no significant differences at baseline. The percentage of 
patients that reported to be treated successfully was 36% in SCIT and 20% in UC 
after two years. Other health outcomes did not differ between SCIT and Usual Care. 
Two-year costs of SCIT were 2946 Euro per patient. There was no difference in other 
costs. Cost per additional successfully treated patient were about 15,000 Euro. For 
the other outcomes, SCIT was dominated by UC. ConClusions: This study could 
not support the cost-effectiveness of SCIT. A restriction in the indication of SCIT 
to patients with severe persistent rhinitis, not sufficiently responsive to maximum 
symptomatic therapy may improve cost-effectiveness.
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objeCtives: To determine the relative impact of treatment with Oralair®, Grazax®, 
Alutard® or symptomatic drug treatment (SDT) on clinical effects and health care 
costs in subgroups of adults and children with grass pollen-induced allergic rhinitis 
(AR) in Germany. The cost-effectiveness of Oralair® has been demonstrated in a 
mixed population in previous research. Methods: The effects of three years of drug 
treatment on quality-adjusted life years (QALYs) and associated costs were assessed 
using a Markov model with a nine-year time horizon. Symptom score data were 
extracted, and the relative efficacy on QALYs was assessed through a network meta-
analysis (i. e. indirect comparison) of placebo-controlled, clinical trial data in adults 
and children. Patient symptom scores were translated into the impact on quality of 
life by means of published sources. Costs associated with drug treatment and other 
health care resources, including Statutory Health Insurance payments and patient 
co-payments, were estimated. The incremental costs and QALYs were generated 
accordingly. The uncertainty around the model outcomes was determined by means 
of sensitivity analyses. Results: In adults, the analysis predicted more QALYs for 
Oralair® relative to Grazax®, 0.008 (95%CI: -0.043; 0.062) and Alutard®, 0.028 (95%CI: 
-0.029; 0.093), combined with incremental costs of -€ 1,272 (95%CI: -€ 1,530; -€ 999) 
and -€ 129 (95%CI: -€ 389; € 160) per patient, respectively. Hence, Oralair is dominant 
relative to Grazax® and Alutard® in adults. The incremental cost-effectiveness ratio 
was estimated at € 15,503 per QALY relative to SDT. Similar results were observed 
in children, with the exception of Alutard® (lack of data). The sensitivity analyses 
suggest that results were mostly driven by drug-specific clinical effects on symptom 
score, drug costs, inputs for immunotherapy discontinuation, and length of the pol-
len season. ConClusions: Oralair® is cost-effective relative to Grazax®, Alutard® 
and SDT in grass pollen-induced AR in Germany. Findings were confirmed again 
and supported by extensive sensitivity analyses.
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alone from 3.6% to 45.8%, and omalizumab from 0% to 6%. Annual hospitalizations 
rates and emergency visits decreased by 78% and 75% respectively. The ICER was 
1800€ per controlled patient per year. ConClusions: Managing asthma patients 
in a specialized AC is cost-effective and has significant impact on patient control, 
indicating better survival and quality of life for the patient according to published 
literature evidence.
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objeCtives: A health economic assessment was conducted to determine the 
relative impact of treatment with Oralair® or Grazax® on clinical effects and 
health care costs in patients with grass pollen-induced allergic rhinitis (AR) in 
Germany. Methods: The effects of three years of drug treatment on symptom-
free days (SFDs) and associated costs were assessed using a health economic 
Markov model with a nine-year time horizon. The relative efficacy on SFDs was 
assessed through a network meta-analysis (i. e. indirect comparison) of 4-year, 
placebo-controlled, clinical trial data. Costs associated with drug treatment and 
other health care resources, including Statutory Health Insurance payments and 
patient co-payments, were calculated. The incremental costs and SFDs gained for 
Oralair® relative to Grazax® were generated accordingly. The uncertainty around 
the model outcomes was determined by means of sensitivity analyses. Results: 
The base case analysis over 9 years predicts a total of 206.6 discounted SFDs for 
Oralair®relative to 205.1 for Grazax®, thus resulting in 1.5 (95%CI: -25.0; 29.3) addi-
tional SFDs gained with Oralair®. Total discounted costs are estimated at € 1,696 and 
€ 2,968 for Oralair® and Grazax®, respectively, with incremental costs predicted at 
-€ 1,272 (95%CI: -€ 1,530; -€ 999). Hence, Oralair® may be classified as the dominant 
strategy, as additional effects are combined with considerable cost savings. The 
sensitivity analyses suggest that results were mostly driven by drug-specific clini-
cal effects on SFD, inputs for immunotherapy discontinuation, and length of the 
pollen season. The predicted cost savings were driven by the difference in treat-
ment costs. ConClusions: Oralair® is cost-effective relative to Grazax®in patients 
with grass pollen-induced AR in Germany. Findings are confirmed by extensive 
sensitivity analyses.
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objeCtives: To evaluate the potential economic impact of the 100% whey-based 
partially hydrolyzed infant formula (PHF-W) in comparison with a cow’s milk stand-
ard formula (SF) in the prevention of atopic dermatitis (AD) in at-risk children at 
the age periods 0–12 and 0–36 months in Russia. Methods: The Excel model was 
constructed to estimate costs of artificial feeding with PHF-W vs SF and expected 
AD cases treatment. The model was based on the results of meta-analysis of rand-
omized controlled trials (RCTs), literature data and the results of the expert survey. 
The costs of artificial feeding and AD treatment were calculated from the positions 
of different payers: health care system, family, and society as a whole. The incre-
mental cost-effectiveness ratio (ICER) per averted AD case was calculated for PHF-W 
vs SF. Results: From health care system point of view the use of PHF-W uniquely 
lead to cost savings. If we consider all costs from the societal perspective PHF-W 
vs SF requires additional costs in the first year of baby’s life, but in leads to cost 
savings in a 3-year horizon. From the perspective of the at-risk child’s family arti-
ficial feeding costs will increase from 266 to 408 Euro for PHF-W vs SF. However the 
likelihood of AD development in a child will decrease from 15 to 8% in the first year 
and from 27 to 19% over three years and accordingly this will prevent AD treatment 
costs. ConClusions: Using PHF-W for the AD preventionin high-risk children have 
benefits for both the health system and for individual family.
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objeCtives: In France, continuous positive airway pressure (CPAP) is recom-
mended as first-line treatment for patients with severe OSAHS or mild-to-mod-
erate OSAHS with high cardiovascular risk. Dental devices are recommended 
as second-line treatment for these patients and can be suggested as first-line 
treatment for mild-to-moderate OSAHS patients without high cardiovascular 
risk. Lifestyle advice is recommended for overweight patients. This study aims to 
assess the cost-effectiveness of these treatments for mild-to-moderate OSAHS 
patients. Methods: This study was commissioned by the French National 
Authority for Health (HAS) and followed their recommendations. A Markov model 
was developed to simulate the lifetime progression of a cohort of mild-to-mod-
erate adult OSAHS patients. CPAP was compared with dental devices, lifestyle 
advice and no treatment. Daytime sleepiness, cardiovascular disease and road 
traffic accidents were taken into account. Clinical parameters were taken from 
international publications. Costs were retrieved from the French national health 
insurance databases: Assurance Maladie and Technical Agency of Information on 
